title: The Second National Acute Spinal Cord Injury Study.
abstract: In 1990, the Second National Acute Spinal Cord Injury Study reported that high-dosage methylprednisolone improves neurologic recovery in spinal-injured humans. The study showed that patients who received the drug within 8 hr after injury improved, whereas those who received the drug later did not. The drug significantly increased recovery even in severely injured patients who were admitted with no motor or sensory function below the lesion, contradicting a long-held dogma that such patients would not recover. Some researchers, however, have questioned the stratification of the patient population, the use of summed neurologic change scores, and the absence of functional assessments. The stratification by injury severity and treatment time was planned a priori and based on objective criteria. Detailed analyses revealed no differences between groups attributable to stratification or randomization. While multivariate analyses of the summed neurologic scores were used, the conclusions were corroborated by other analytical approaches that did not rely on summed scores. For example, treatment with methylprednisolone more than doubled the probability that patients would convert from quadriplegia or paraplegia to quadriparesis or paraparesis, analgesia to hypalgesia, and anesthesia to hypesthesia. The treatment also significantly improved neurologic scores in lumbosacral segments, indicating that beneficial effects were not limited to segments close to the lesion site. The treatment did not significantly affect mortality or morbidity. The study strongly suggests that methylprednisolone has significant beneficial effects in human spinal cord injury, that these effects occur only when the drug is given within 8 hr, and that it helps even in patients with severe spinal cord injuries. These conclusions have important implications for spinal cord injury care and research.
authors.affiliation: Department of Neurosurgery, New York University Medical Center, New York.
authors.forename: W
authors.initials: W
authors.lastname: Young
authors.forename: M B
authors.initials: MB
authors.lastname: Bracken
mesh_terms: D004334:Drug Administration Schedule; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use*; D009043:Motor Activity; D012677:Sensation; D013119:Spinal Cord Injuries / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery
chemical_list: D008775:Methylprednisolone